W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

News

Position of the Transparency Council – Tremfya (guselkumabum)

more...

Opinion of the Transparency Council – methotrexatum

more...

Opinion of the Transparency Council – cyclophosphamidum

more...

Opinion of the Transparency Council – azathioprinum

more...

Position of the Transparency Council – Empliciti (elotuzumab)

more...

Position of the Transparency Council – Ontozry (cenobamat)

more...

Opinion of the Transparency Council – recommended medical technologies, actions to be carried out under health policy programmes and the implementation conditions for the glaucoma prevention programmes

more...

Position of the Transparency Council – qualifying of health care services financed from the entrusted budget and provided on the order of a primary care physician

more...

The Meeting of the Tariffs Council No. 21/2022 of 01.09.2022

more...

The Meeting of the Transparency Council No. 34/2022 of 29.08.2022

more...

Communication – new tariffs covering neonatal care

more...

The Meeting of the Tariffs Council No. 20/2022 of 25.08.2022

more...

Recommendation of the President – Rezurock (belumosudil)

more...

The Meeting of the Transparency Council No. 33/2022 of 22.08.2022

more...

Opinion of the Transparency Council – health policy programme on thyroid diseases (Town of Leszno)

more...

Opinion of the Transparency Council – health policy programme on infertility treatment (Rzeszów)

more...

Opinion of the Transparency Council – health policy programme on breast cancer (Municipality of Toszek)

more...

Position of the Transparency Council – Inovelon (rufinamide)

more...

Position of the Transparency Council – Fycompa (perampanel)

more...

Opinion of the Transparency Council – changes to the drug programme B.82

more...

Opinion of the Transparency Council – active substance etanercept

more...

Opinion of the Transparency Council – changes to the drug programme B.44

more...

Position of the Transparency Council – Ozurdex (dexamethasone)

more...

Position of the Transparency Council – Tremfya (guselkumab)

more...